In this preprint from our September 2011 issue, authors from Lamdagen describe a new label-free sensor platform for bioprocess development, monitoring, and validation during therapeutic antibody manufacture. The technology, referred to as localized surface plasmon resonance (LSPR), is made possible through the creation and use of nanostructured metallic films. The two areas most likely to benefit from this new technology are process development and monitoring and Quality Control. More effective process development efforts can lower costs of therapeutic proteins at clinical scales. However, better technology is needed to effectively and economically develop the process and thereafter be used during manufacturing to monitor the process. Regulatory requirements play a large role in determining how the process will be developed and later implemented